Future Science Group

Future Science Group is less a single programme than a shared feed for several specialist biomedical outlets. Each episode names its outlet: RegMedNet for regenerative medicine, OC Talks from Oncology Central for cancer, and a Bioanalysis Zone spotlight on flow cytometry. The interviewers are mostly editors. Khadija, a digital editor of RegMedNet, leads several conversations, Jade Parker, Senior Editor of Oncology Central, leads another, and Emma Hall hosts the sponsored features. The structure is dependable. A guest introduces themselves and their role, works through a series of questions, and the episode ends with a warm thank-you. Deborah Ojutalayo, who goes by Debs, describes discovery work on AAV-based gene therapies for neurodegenerative diseases, frontotemporal dementia among them. That work is hands-on: cell culture, cell-based assays and the evaluation of therapeutic candidates. The same interview follows a path through biomedical science, biochemistry and then immunology, a turn Ojutalayo credits to COVID. Guillermo Ameer, a professor of biomedical engineering at Northwestern University, speaks plainly about why new materials are hard to bring to patients. Regulatory approval is slow and costly, and the field needs far more investment than AI or social media platforms, which can earn large returns on modest funding. Baba Inusa, a pediatric hematologist and professor at King's College London, discusses sickle cell disease and thalassemia. That conversation covers gene therapy and curative approaches, the disappointment of two major therapies being withdrawn, and why early diagnosis improves care for an inherited disorder. On the oncology side, Leanne Bailey of the NCI Centre to Reduce Cancer Health Disparities lists risk factors associated with rising early-onset cancer, including obesity, environmental exposure, sleep patterns, physical inactivity, microbiota and ultra-processed foods. The discussion also covers the 2021 decision to lower the US colorectal screening age to 45 and its effect on screening uptake. Equity connects episodes that otherwise have little in common. Sean Kimbrough and Kenesha Webb of Morehouse School of Medicine share early data showing differences by sex in inflammatory markers and cytokines, and explain their interest in comparing rural and urban participants and African American participants with other groups. The sponsored episodes are announced at the start, Icon for flow cytometry and Merck KGaA, Darmstadt, Germany for biomarker discovery. They also lean hardest on method, with Long Nguyen and Henko Tadema of Icon describing cell therapy monitoring as a pharmacokinetic assay run by flow cytometry. Several episodes point to companion material, such as a spotlight page, an infographic and a short video. For a first listen, 'Innovating and developing tissue engineering beyond replacement: a podcast with Guillermo Ameer' suits anyone curious about why lab advances stall before the clinic, while 'Tackling the rise in early onset cancer: From research to health equity' is the most public-health minded. The feed's main offer is direct access: working scientists and clinicians explaining in their own words what they do and what stands in the way.